Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Japan’s Top Banks to Gain Access to Anthropic’s Claude Mythos AI Model 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Coles “Down Down” Ruling Sparks Fresh Scrutiny of Australian Supermarket Pricing 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Kuaishou Stock Jumps on Kling AI IPO Plans and $20 Billion Valuation 
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment 
Elon Musk’s China Influence Faces New Challenges Amid Rising EV Competition 
Why the future of marijuana legalization remains hazy despite high public support 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Novo Nordisk shares plunged more than 10% in mid-morning trading in Copenhagen on Monday after the pharmaceutical giant announced that its experimental obesity drug, CagriSema, failed to meet a primary endpoint in a closely watched clinical trial. The update intensifies competition in the rapidly expanding weight loss drug market, where Novo Nordisk faces mounting pressure from rival Eli Lilly.
The 84-week open-label head-to-head study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly’s blockbuster obesity treatment, Tirzepatide, in reducing body weight. According to Novo Nordisk, patients treated with CagriSema achieved an average weight loss of 23%, while those receiving Tirzepatide recorded a superior 25.5% reduction. As a result, the trial did not meet its primary objective of proving that CagriSema was not lagging behind Tirzepatide in weight loss efficacy.
The disappointing trial results sent Novo Nordisk stock sharply lower, adding to a challenging year for the Danish drugmaker. In 2025, Novo shares have fallen by 49%, reflecting investor concerns over intensifying competition and shifting dynamics in the obesity treatment sector. The company previously secured a dominant position with its blockbuster drugs Wegovy and Ozempic, both of which fueled significant growth amid surging global demand for weight management medications.
However, competition has grown fiercer, particularly from Eli Lilly, whose Tirzepatide has gained significant traction. Additionally, telehealth providers offering lower-cost compounded alternatives have further pressured pricing and market share.
Despite the setback, Novo Nordisk confirmed that CagriSema was submitted to the U.S. Food and Drug Administration (FDA) for approval in December, with a regulatory decision expected by late 2026. The company recently announced board-level changes, including the appointment of industry veterans and Lars Rebien Sorensen as chairman, signaling a strategic push to strengthen leadership and respond more aggressively to U.S. market challenges.
Investors will now closely monitor regulatory developments and Novo Nordisk’s strategy to defend its position in the booming obesity drug market.
